# Drug Development and Delivery: Drug Development and Delivery Magazine

> Drug Development \& Delivery is a print and online publisher that presents the latest scientific methods in drug development for professionals\.

Generated by Yoast SEO v27.9, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Ask AI](https://drug-dev.com/ask-ai/)
- [About Us](https://drug-dev.com/about-us/)
- [E\-Books](https://drug-dev.com/e-books/)
- [Advertise Where AI and Pharma Decision\-Makers  Look First](https://drug-dev.com/ai-for-pharma/)
- [Media Planner](https://drug-dev.com/media-planner/)

## Posts
- [Evonik partners with evitria to accelerate early biologics development](https://drug-dev.com/evonik-partners-with-evitria-to-accelerate-early-biologics-development/)
- [2026 Nasal \& Inhalation Drug Development \& Delivery eBook: Drug Repurposing Creates New Market Opportunities](https://drug-dev.com/drug-repurposing-creates-new-market-opportunities/): In this exclusive seventh annual nasal and inhalation eBook, Drug Development \& Delivery highlights how these routes of administration are bringing new life to orphaned drugs and open new opportunities for treatment beyond pulmonary and respiratory diseases\. We also explore the challenges of nose\-to\-brain delivery, next\-generation propellants, overcoming the limitations of dry powder inhalers, and successful formulation strategies\.
- [Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on\-body injector](https://drug-dev.com/sanofis-subcutaneous-sarclisa-escena-approved-in-the-us-as-first-anticancer-treatment-administered-via-on-body-injector/)
- [Atsena Therapeutics Selects ATSN\-401 Clinical Candidate, a Potential Best\-in\-Class Gene Therapy for Stargardt Disease](https://drug-dev.com/atsena-therapeutics-selects-atsn-401-clinical-candidate-a-potential-best-in-class-gene-therapy-for-stargardt-disease/)
- [Gattefossé accelerates production ramp\-up at its Lufkin facility with eight validated ingredients](https://drug-dev.com/gattefosse-accelerates-production-ramp-up-at-its-lufkin-facility-with-eight-validated-ingredients/)

## Videos
- [Small Batches, Big Impact: The New Realities of CDMO Formulation Development](https://drug-dev.com/videos/small-batches-big-impact-the-new-realities-of-cdmo-formulation-development/)
- [Enhancing Drug Bioavailability: Solubility Techniques and Innovations](https://drug-dev.com/videos/enhancing-drug-bioavailability-solubility-techniques-and-innovations/)
- [2026 Drug Development Outlook: What Industry Insiders Are Saying](https://drug-dev.com/videos/2026-drug-development-outlook-what-industry-insiders-are-saying/)
- [Better Bioavailability Faster Timelines with Ascendia Pharmaceutical Solutions](https://drug-dev.com/videos/better-bioavailability-faster-timelines-with-ascendia-pharmaceutical-solutions/)

## Webinars
- [WEBINAR ON DEMAND: Why early matters: Data\-driven strategies to de\-risk OSD development](https://drug-dev.com/webinars/webinar-on-demand-why-early-matters-data-driven-strategies-to-de-risk-osd-development/): This on\-demand webinar focuses on how data\-driven characterization, predictive modeling, and Quality by Design \(QbD\) approaches help teams identify and address risks earlier—when decisions are more flexible and impacts easier to manage, before scale\-up begins\.
- [ON\-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules](https://drug-dev.com/webinars/on-demand-webinar-drug-product-design-for-delivery-of-challenging-molecules/): In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products\.
- [WEBINAR \- Vytal: The RTU Snap\-Fit System for Container Closure Solutions – Setting the Standard for the Future](https://drug-dev.com/webinars/vytal-the-rtu-snap-fit-system-for-container-closure-solutions-setting-the-standard-for-the-future/): In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies\. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell\-based therapies, which now represent some of the most successful pharmaceutical products globally\.
- [WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing](https://drug-dev.com/webinars/webinar-precision-at-scale-enabling-novel-therapeutics-with-nanoparticle-manufacturing/): Watch this on\-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle\-based therapeutics from early R\&D to commercial stages\. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials\.\.\.\.\.
- [WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development](https://drug-dev.com/webinars/webinar-introducing-key-concepts-in-tableting-research-unleashing-essential-concepts-and-strategies-for-enhanced-formulation-development/): Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity\. These issues can lead to manufacturing inefficiencies\.\.\.\.

## Whitepapers
- [WHITE PAPER \- Small Molecules: Choosing the Right Development Path](https://drug-dev.com/whitepapers/white-paper-small-molecules-choosing-the-right-development-path/): This white paper outlines a structured, risk\-minimized approach to early CMC \(Chemistry, Manufacturing, and Controls\) development for small\-molecule drugs—particularly for startups and virtual pharma companies with limited resources\.
- [eBook \- An Introduction to PLG Polymers for Long‑Acting Drug Delivery](https://drug-dev.com/whitepapers/whitepaper-an-introduction-to-plg-polymers-for-long-acting-drug-delivery/)
- [eBook \- An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers](https://drug-dev.com/whitepapers/white-paper-an-insoluble-problem-overcoming-oral-drug-solubility-challenges-with-functional-polymers/): There are three key factors that need to be controlled when designing a drug product for solubility enhancement: the polymeric carrier; the manufacturing process; and the match to the desired API\. By controlling these three factors bioavailability, drug release profile and manufacturability of your final drug product can be controlled\.
- [WHITEPAPER \- From Service Provider to Strategic Partner](https://drug-dev.com/whitepapers/whitepaper-from-service-provider-to-strategic-partner/): As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability\.
- [WHITE PAPER \- Stop Guessing\. Start Predicting: Rethinking Early Oral Drug Development](https://drug-dev.com/whitepapers/white-papaer-stop-guessing-start-predicting-rethinking-early-oral-drug-development/): This article explores how AI\-driven predictive insights reduce uncertainty in early oral drug development, enabling smarter decisions on solubility, dosing, stability, and scale\-up while preserving API, accelerating timelines, and de\-risking clinical success \.

## Company Profiles
- [Aprecia Pharmaceuticals](https://drug-dev.com/company-profiles/aprecia-pharmaceuticals/)
- [Proveris Scientific](https://drug-dev.com/company-profiles/proveris-scientific/)
- [Ensera](https://drug-dev.com/company-profiles/ensera/)
- [Upperton Pharma Solutions ](https://drug-dev.com/company-profiles/upperton-pharma-solutions/)
- [Lifecore Injectables CDMO](https://drug-dev.com/company-profiles/lifecore/)

## Tech Showcase
- [CDMO Services](https://drug-dev.com/tech_showcase/cdmo-services-2/)
- [Contract Development \& Manufacturing](https://drug-dev.com/tech_showcase/contract-development-manufacturing-2/)
- [Pharma Solutions](https://drug-dev.com/tech_showcase/pharma-solutions-2/)
- [Global CRMO](https://drug-dev.com/tech_showcase/global-crmo-2/)
- [CMC Services](https://drug-dev.com/tech_showcase/cmc-services/)

## Video Spotlights
- [Milipore Sigma \- Partek](https://drug-dev.com/video_spotlights/milipore-sigma-partek/)
- [Ajinomoto](https://drug-dev.com/video_spotlights/ajinomoto/)

## Industry Events
- [PDA Universe of Pre\-Filled Syringes and Injection Devices Conference 2026](https://drug-dev.com/industry_events/pda-universe-of-pre-filled-syringes-and-injection-devices-conference-2026/)
- [AAPS PharmSci 360](https://drug-dev.com/industry_events/aaps-pharmsci-360/)
- [CPhI Milan](https://drug-dev.com/industry_events/cphi-milan/)
- [PODD \(Partnership Opportunities in Drug Delivery\)](https://drug-dev.com/industry_events/podd-partnership-opportunities-in-drug-delivery/)

## Issues
- [Nasal \& Inhalation eBook 2026](https://drug-dev.com/issues/nasal-inhalation-e-book-2026/)
- [June 2026](https://drug-dev.com/issues/june-2026/)
- [May 2026](https://drug-dev.com/issues/may-2026/)
- [March/April 2026](https://drug-dev.com/issues/march-april-2026/)
- [January/February 2026](https://drug-dev.com/issues/january-february-2026/)

## Expert Content
- [Navigating FDA QMSR in 2026 ](https://drug-dev.com/expert-content/navigating-fda-qmsr-in-2026/): How medical device manufacturers can move beyond checklist compliance and build inspection\-ready quality systems 
For years, many medical device manufacturers approached FDA inspections through a familiar lens: prepare documents, review subsystem requirements, rehearse likely questions, and demonstrate compliance against a known framework\.
- [eBook: Understanding the Foundation of LNP Formulation Success](https://drug-dev.com/expert-content/ebook-understanding-the-foundation-of-lnp-formulation-success/): Lipid nanoparticles \(LNPs\) are one of the most significant advances in drug delivery in decades\. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids\.
- [On\-Demand Presentation: Analytical Strategy \& Challenges for ADC](https://drug-dev.com/expert-content/on-demand-presentation-analytical-strategy-challenges-for-adc/): Global Vice President of Analytical \& Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry\.
- [Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products](https://drug-dev.com/expert-content/avoiding-recalls-how-to-ensure-sterility-in-ophthalmic-products/): In the wake of several high\-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety\.
- [America’s Next Healthcare Crisis Is Already Here \- And We’re Not Ready](https://drug-dev.com/expert-content/americas-next-healthcare-crisis-is-already-here-and-were-not-ready/): Bryn L\. Dubin, Master’s Student at the LBJ School of Public Affairs studying health and economic policy\. Dubin has federal and state legislative and policy analysis experience\.

## Categories
- [Market News \& Trends](https://drug-dev.com/category/market-news-and-trends/)
- [Formulation Development](https://drug-dev.com/category/formulation-development/)
- [Bio Platforms](https://drug-dev.com/category/bio-platforms/)
- [Exclusive Online Content](https://drug-dev.com/category/exclusive-online-content/)
- [Contract Services](https://drug-dev.com/category/contract-services/)

## Optional
- [Sitemap index](https://drug-dev.com/sitemap_index.xml)